Why It Matters

The Animal Health Institute faces a fundamental challenge: securing adequate government funding and favorable regulatory conditions for animal medicines amid competing congressional priorities. At stake is the industry’s ability to innovate and deliver vaccines and therapeutics during critical animal health crises.

The immediate threat is twofold—the ongoing avian influenza outbreak and a severe veterinary workforce shortage—both of which underscore why animal pharmaceutical development requires sustained appropriations for the FDA’s Center for Veterinary Medicine and USDA’s Center for Veterinary Biologics.

Legislative solutions AHI is pursuing include the Innovative FEED Act, which would streamline regulatory pathways for new animal health products, alongside robust budget support during the FY26 appropriations process.

By the Numbers

The Animal Health Institute reported $50,000 in fourth quarter in-house lobbying expenditures. Over two decades, AHI has spent $4.4 million across 168 total filings, establishing itself as a durable player in veterinary medicine policy.

AHI employs a hybrid lobbying model combining internal operations with strategic external partnerships. The in-house team accounts for 78 filings and $2.59 million in total spending. Its primary external partner, the Torrey Advisory Group, was retained in 2020 and has collected $840,000 across 25 disclosures, focusing on appropriations and trade issues.

AHI’s priorities have remained stable, with budget and appropriations dominating 131 disclosure mentions, followed by trade issues (92), animal health (71), and agriculture (61).

The Agenda

AHI’s primary focus remains securing federal funding for the FDA’s Center for Veterinary Medicine and the USDA’s Center for Veterinary Biologics—a consistent top priority across two decades of advocacy.

Beyond appropriations, AHI is actively engaged on several pending bills:

  • The Innovative FEED Act of 2025 would create a streamlined regulatory pathway for animal feed additives, directly benefiting AHI members.

  • The Expanded Food Safety Investigation Act of 2025 would expand FDA oversight of livestock operations, potentially imposing new regulatory burdens.

  • The PAW Act of 2025 would allow pet owners to use health savings accounts for veterinary expenses, expanding the companion animal pharmaceutical market.

Broader Context

Congress is actively legislating on animal health issues central to AHI’s mission. The Innovative FEED Act enjoys bipartisan support and would benefit AHI members seeking to bring innovative products to market. Meanwhile, the Expanded Food Safety Investigation Act could impose new regulatory burdens on livestock producers.

A critical veterinary workforce shortage threatens disease response capabilities, while highly pathogenic avian influenza outbreaks underscore the importance of vaccines and therapeutics. Congressional focus on animal disease preparedness creates opportunities for AHI to position its members’ products as essential infrastructure.

Between The Lines

Key congressional activities demonstrate bipartisan engagement on animal health. The House Appropriations Subcommittee marked up the FY26 spending bill addressing FDA and USDA funding priorities central to AHI’s advocacy. A bipartisan group including Sen. Amy Klobuchar pressed the USDA on staffing losses at APHIS affecting disease prevention capacity.

Senators Cindy Hyde-Smith and Amy Klobuchar announced expansion of the Senate Veterinary Medicine Caucus addressing rural veterinarian shortages, while the House Homeland Security Committee held hearings on agroterrorism threats linking animal health to national security.

Competitive Landscape

AHI operates within a crowded advocacy ecosystem where major industry competitors pursue parallel strategies. Zoetis Inc. spent $200,000 on lobbying in Q4 2025 alone—four times AHI’s expenditure—focusing on antimicrobial resistance and support for the PAW Act. Elanco Animal Health similarly lobbies on Animal Drug User Fee Act reauthorization.

The American Feed Industry Association backs legislation promoting U.S. animal food supply chain resilience, indicating a coordinated industry effort across multiple organizations.

The Bottom Line

AHI’s $50,000 fourth 2025 lobbying spend continues a two-decade advocacy presence focused on FDA and USDA funding, animal drug regulations, and trade policy. The current congressional environment shows bipartisan support for the Innovative FEED Act, while expanded food safety oversight could increase regulatory burdens. The combination of avian flu emergencies and veterinary workforce shortages validates AHI’s appropriations strategy but intensifies competition for policy influence within a crowded legislative agenda.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article